| Literature DB >> 31212019 |
Sofiya Hupalo1, Courtney A Bryce2, Debra A Bangasser3, Craig W Berridge4, Rita J Valentino5, Stan B Floresco2.
Abstract
The neuropeptide, corticotropin-releasing factor (CRF), is a key modulator of physiological, endocrine, and behavioral responses during stress. Dysfunction of the CRF system has been observed in stress-related affective disorders including post-traumatic stress disorder, depression, and anxiety. Beyond affective symptoms, these disorders are also characterized by impaired cognition, for which current pharmacological treatments are lacking. Thus, there is a need for pro-cognitive treatments to improve quality of life for individuals suffering from mental illness. In this review, we highlight research demonstrating that CRF elicits potent modulatory effects on higher-order cognition via actions within the prefrontal cortex and subcortical monoaminergic and cholinergic systems. Additionally, we identify questions for future preclinical research on this topic, such as the need to investigate sex differences in the cognitive and microcircuit actions of CRF, and whether CRF may represent a pharmacological target to treat cognitive dysfunction. Addressing these questions will provide new insight into pathophysiology underlying cognitive dysfunction and may lead to improved treatments for neuropsychiatric disorders.Entities:
Keywords: Acetylcholine; Basal forebrain; Cognitive flexibility; Corticotropin-releasing factor (CRF); Cost/benefit decision-making; Dopamine (DA); Dorsal raphe nucleus (DR); Effort-related choice; Locus coeruleus (LC); Medial septum (MS); Motivation; Norepinephrine (NE); Nucleus; Object location memory; Prefrontal cortex (PFC); Serotonin (5-HT); Sex differences; Sustained attention; Ventral tegmental area (VTA); Working memory; accumbens (NAc)
Year: 2019 PMID： 31212019 PMCID： PMC6692202 DOI： 10.1016/j.neubiorev.2019.06.010
Source DB: PubMed Journal: Neurosci Biobehav Rev ISSN： 0149-7634 Impact factor: 8.989